A subset of B cell chronic lymphocytic leukaemia (CLL) is familial. Lack of large families makes it attractive to exploit methods in addition to genetic linkage analysis for the identification of a susceptibility locus. One strategy that can localise regions of the genome that may harbour tumour suppressor genes is to identify regions of chromosomal imbalance using comparative genomic hybridisation (CGH) analysis. We examined 24 familial CLL cases by CGH analysis. Losses that are documented as arising frequently in sporadic CLL were observed at a comparable frequency in familial CLL. However, gains and losses in two regions of the X chromosome -Xp11.2-p21 and Xq21-qter -appear more common in familial CLL than in sporadic CLL. This suggests these regions may harbour a susceptibility locus for CLL. There is also some evidence that chromosome regions 2p12-p14 and 4q11-q21 may harbour predisposition genes.
Introduction
B cell chronic lymphocytic leukaemia (CLL) is the most common form of leukaemia, accounting for around 30% of all leukaemia cases. 1 The aetiology of CLL is largely unknown, however, there is increasing evidence from epidemiological studies that a proportion of CLL has an inherited basis. 2 Family studies suggest that the most plausible genetic model for inherited predisposition is a dominantly acting gene with pleiotropic effects since, in some families, CLL co-exists with other lymphoproliferative disorders (LPD). 2 Most CLL families are small and so identification of predisposition genes through genome-wide linkage searches may be difficult, as the number of families required may be prohibitively large. A CLL susceptibility gene is likely to be a tumour suppressor and so an alternative strategy is to look for a region of recurrent genomic loss in tumour cells from familial cases. Comparative genomic hybridisation (CGH) provides an attractive strategy to examine the whole genome for regions of chromosomal loss or gain. Here we report an analysis of 24 familial cases of CLL using CGH analysis.
Patients and methods
Twenty-four families with more than one individual affected with CLL were identified through Haematology Departments in the United Kingdom, Canada, Israel and Chile. The age at Table 1 . Diagnoses of CLL in all cases were based on standard clinicohaematological and immunological criteria. The study was undertaken with informed consent and local ethical review board approval.
Venous blood samples were obtained from patients. Mononuclear cells were obtained by centrifugation over Histopaque (Sigma, Poole, UK) and stored in dimethyl sulphoxide/fetal calf serum. The separated cells obtained contained in excess of 75% tumour cells in all cases as estimated by immunophenotyping (Table 1) . DNA was prepared using standard procedures. CGH, capture of digital images and their analysis was carried out as previously described. 3, 4 Briefly, 1 g of normal and tumour sex-matched DNAs were directly labelled by nick translation with either fluorescein-12-dUTP or rhodamine-12-dUTP (Amersham Pharmacia, UK). The reaction was modified in order to produce DNA fragments 500-2000 bp in size as assessed on a 1% agarose gel. 500 ng of each labelled DNA plus 25 g of Cot 1 DNA (BRL Gibco, Life Technologies, Paisley, UK) were co-hybridised to normal denatured metaphases for 48 h at 37°C before washing and mounting in anti-fade with 0.1 g/ml DAPI as a counterstain. Images were captured using a cooled CCD camera (Photometrics) with SmartCapture software (Digital Scientific, UK). CGH analysis was carried out using the Quips-XL software (Vysis Ltd, UK). At least five representative images were fully analysed and the results from these were studied separately and also combined to produce an average fluorescence ratio for each chromosome. A copy number change was indicated when the mean fluorescence ratio lay outside the normal standard deviation of the mean ratio determined in normal to normal control experiments (1.0 ± 0.15).
Fluorescent in situ hybridisation (FISH) was performed as previously described. 5 Briefly, mononuclear cells from fresh blood samples were fixed and cell suspensions dropped on to microscope slides. These were hybridised with probes to detect changes in allele number at 6q21, 11q23, 12 cen, 13q14, 17 cen and 17p13.1. The probes were respectively: YAC963D6 (S Stilgenbauer, University of Ulm, Heidelberg Germany); YAC755B11 (S Stilgenbauer); D13S25 (160 kbp), CEP12; CEP17 and TP53 (130 kbp) (all from Vysis Ltd, UK). DNA was extracted by standard methods and labelled by nick-translation (Roche Diagnostics Ltd, UK). Dual colour FISH was carried out overnight at 37°C. Indirect detection employed flurrochrome-conjugated antibodies (Vector Laboratories Ltd, UK). Visualisation used an Axioskop microscope (Zeiss, UK). Signal numbers were enumerated in 200 cells for each fluorochrome. The probes YAC963D6 and YAC755B11 were co-hybridised with a control probe (YAC HSCE7e465 at 7q21; L Osborne, Dept Genetics, The Hospital for Sick Chil-SPOTLIGHT dren, Toronoto, Canada). Only nuclei demonstrating two signals for the control probe were scored. Cut-off levels were set at 3× standard deviation of the mean number of variants seen in 10 normal controls.
Results
Chromosomal imbalances detected in 24 familial CLL cases examined by CGH analysis are summarised in Figure 1 The results of this analysis are summarised in Table 2 for those familial CLL patients where the same samples were available for analysis by FISH and by CGH. The results provide evidence for concordance between FISH and CGH data. This suggests that the CGH threshold values used (1.15 and 0.85) were representative of regions of chromosomal gain or loss. Overall in the study the false positive rate between CGH and corresponding FISH analyses is less than 5%.
CGH detected 63 losses and 98 gains in the 24 samples. The average number of abnormalities in each case was seven (range 1-14). Gains or losses were most frequently observed on chromosome X (18/24: 75% of cases), chromosome 11 (13/24: 54%) and chromosome 2 (13/24: 54%). The most frequent losses were on chromosome X (8/24: 33%), chromosome 2 (6/24: 25%), chromosome 4 (6/24: 25%) and chromosome 5 (4/24: 17%). The most frequent gains were on chromosome X (10/24: 42%); chromosome 11 (9/24: 38%); chromosome 1 (8/24: 33%); chromosome 3 (7/24: 29%).
Considering the four families in which two affected individuals were examined by CGH, 17 chromosomal gains and 34 chromosomal losses were recorded. None of the gains were concordant between family members except in family 60, Additionally they had overlapping losses on chromosomes 2p12-p21, 4q12-q22, 9q21-q22 and 16q11-q24. Mother and son in family 82 had concordant overlapping losses on chromosomes 13q14-q21 and 17p11.1-pter.
Discussion
This CGH study was undertaken to investigate associations between familial CLL and specific chromosomal abnormalities in tumour cells. Determining copy number at five loci provided validation of the CGH findings by FISH. Based on these results we estimate that the false positive rate is less than 5% strongly indicating that CGH results reliably reflect regions of chromosomal gain or loss. At least one chromosomal gain or loss was detected in each of the 24 cases examined. By contrast, gains or losses were reported in 62% (33/53) of sporadic CLL cases by CGH. 6, 7 This difference in the percentage of samples with chromosomal gains or losses may reflect reduced genomic stability associated with familial CLL or may reflect the restriction of cases selected for this study to samples having at least 75% tumour cells.
In 53 sporadic CLL cases, the most common losses reported in CGH analyses 6, 7 were: 19% showed chromosome 11q loss; 19% chromosome 17p loss; 11% chromosome 13q loss and 8% chromosome 6q loss. In our study of 24 familial cases, 17% showed chromosome 11q loss; 17% chromosome 17p loss; 13% chromosome 13q loss and 4% chromosome 6q loss. These findings suggest that there is little difference between sporadic and familial CLL cases with respect to these chromosomal regions. This similarity between sporadic and familial CLL suggests that none of these four regions of the genome harbour a common familial CLL predisposition gene whose
SPOTLIGHT
Leukemia normal allele is lost by extensive deletion. For chromosome 11q23, this suggestion is consistent with published data 8 showing no significant excess allele sharing in familial CLL at chromosome 11q23.
Losses on chromosome Xp were seen in a third of the familial CLL cases including pairs of cases from two families. The region of loss common to all these cases was Xp11.2-p21. By contrast, losses on chromosome X were not detected in the two published CGH studies on sporadic CLL. 6, 7 Moreover, such losses are rarely seen in cytogenetic analyses: a search of the Mitelman database of cytogenetic aberrations 9 identified five LPD cases with deletions in this region of the X chromosome (three cases with del(X)(q22) and two cases with del(X)(q24)). Gains on chromosome X were observed in 10 familial cases. The common regions of gain encompassed chromosome Xp21 (five cases) and chromosome Xq22-qter (four cases).
Interpretation of chromosomal gains and losses detected by CGH is not straightforward since clonal evolution may involve additional genomic changes. For example, if an early deletion within a given chromosome is followed by duplication of the intact second copy, then the deleted region will be visualised by CGH as a region with no chromosomal imbalance flanked by a region or regions of gain.
With this in mind, we note that the sum of gains and losses at chromosome Xp21 was 12 cases and the sum of gains and losses at chromosome Xq22-qter was eight cases. By contrast, among 53 sporadic CLL cases examined by CGH, 6, 7 just one case showed a gain on chromosome X at Xq22-qter. Interestingly, the regions adjacent to Xp21 and Xq22, called the pseudoautosomal regions have been linked to susceptibility to LPD. 10, 11 Two independent lines of evidence therefore point to the possible involvement of two regions of chromosome X. A feature of CLL is its higher incidence among males than females with a ratio of between 1.5 and 3. A CLL gene on chromosome X might contribute to the male excess.
Losses on chromosome 2 were seen in 6/24 (25%) cases, the most common region of loss being 2p12-2p14. This region was deleted in both members of family 78. Losses in this region are rarely seen in cytogenetic analyses of sporadic LPDs: a search of the Mitelman database 9 identified five cases with chromosome del(2)(p12) and two cases with chromosome del(2)(p14).
Of the five familial CLL cases showing losses on chromosome 4, four shared a common region of loss at chromosome 4q11-q21. This included both members of family 78. Bentz et al 6 reported one sporadic CLL case with genomic loss on the long arm of chromosome 4. The Mitelman database 9 reports three LPD cases with chromosome del(4)(q21).
From our data, familial and sporadic CLL appear to differ by virtue of certain characteristic losses and gains of chromosomal material. Our data implicate Xp11.2-p21, Xq21-qter, 2p12-p14 and 4q11-q21 as chromosome regions that may harbour predisposition genes.
Further studies are, however, required to validate these observations. Studying the CGH patterns for concordance in further affected individuals from multiple case families may provide additional evidence to indicate susceptibility loci for CLL.
